Journal: eBioMedicine

Article Title: A diet rich in fibre and vegetable protein during gestation and lactation shapes maternal immunity, intestinal microbiota and lipid metabolism

doi: 10.1016/j.ebiom.2025.105784

Figure Lengend Snippet: Maternal diet effects on intestinal morphometry and intestinal barrier function at L21 . a–d , Small intestine weight (a) and length (b), cecal content weight (c) and caecum weight (d). Organ weights are expressed as g of tissue/100 g of body weight. e and f, Representative images of histological sections of the jejunum stained with haematoxylin and eosin, 10X (e), and with Periodic acid-Schiff, 10X (f). g-l, Intestinal villi length (g), width (h), area (i), crypts depth (j), villi height/crypts depth ratio (k) and number of goblet cells per intestinal villi (l). m, Relative mRNA expression of intestinal barrier function genes (Ocln, Cldn2 and Cldn4) and mucin genes (Muc2 and Muc3) by real-time PCR, calculated with respect to RD, which corresponds to 1 of transcription (dashed line). Results are expressed as mean ± S.E.M (RD, n = 5; D1, n = 7; D2, n = 8). P values were derived from ANOVA one way followed by Bonferroni post hoc (a–d) and by Dunnett T3 post hoc (g). P values by Kruskal Wallis test followed by multiple comparison with Bonferroni correction (m). The P KW value represents a trend comparing the three dietary groups, therefore, multiple comparisons with Bonferroni correction were not performed.

Article Snippet: The specific TaqMan PCR primers were: Muc2 (Rn01498206_m1, inventoried [I], encoding for Mucin 2), Muc3 (Rn01481134_m1, I, encoding for Mucin 3), Ocln (Rn00580064_m1, I, encoding for Occludin), Cldn2 (Rn02063575_s1, I, encoding for Claudin 2), Cldn4 (Rn01196224_s1, I, encoding for Claudin 4), Gpr43 (Rn02345824_s1, I, encoding for G-protein-coupled receptor 43), Pparγ (Rn00440945_m1, I, encoding for peroxisome proliferator activated receptor γ), Ucp -1, (Rn00562126_m1, I, encoding for uncopling protein 1), Prdm16 (Rn01516224_m1, I, encoding for PR domain containing 16), Cidea (Rn04181355_m1, I, encoding for Cell death-inducing DNA fragmentation factor, alpha subunit-like effector A), IL- 1β (Rn00580432_m1, I, encoding for interleukin-1β), IL-10 (Rn00563409_m1, I), Mcp-1 (Rn00580555_m1, I, encoding for monocyte chemoattractant protein 1), IgA (4331348, made to order), and pIgR (Rn00562362_m1, I, encoding for polymeric immunoglobulin receptor).

Techniques: Staining, Expressing, Real-time Polymerase Chain Reaction, Derivative Assay, Comparison

Journal: Immunity, Inflammation and Disease

Article Title: Alleviating effect of Nexrutine on mucosal inflammation in mice with ulcerative colitis: Involvement of the RELA suppression

doi: 10.1002/iid3.1147

Figure Lengend Snippet: Nexrutine alleviates inflammation and colonic mucosal barrier damage in mice with UC. A mouse model of UC was induced by administration of 3% DSS in drinking water. The model mice were treated with Nexrutine (300 mg/kg or 600 mg/kg) or the positive control regimen Mesalazine (195 mg/kg). (A) Body weight change of mice in each group; (B) DAI score of mice in each group; (C) length of whole colon of mice in each group; (D) pathological injury score in mouse colon tissues evaluated by HE staining; (E) concentrations of IL‐1β, IL‐6, TNF‐α, and IL‐10 in mouse colon tissues analyzed by ELISA kits; (F) expression of MUC3, Claudin‐1, and ZO‐1 in mouse colon tissues determined by IHC assay. In each group, n = 8. Differences were analyzed by the one‐way (B, C, D) or two‐way (A, E, F) ANOVA. * p < .05 versus the control group; # p < .05 versus the DSS group. DAI, disease activity index; DSS, dextran sulfate sodium; HE, hematoxylin and eosin; IHC, immunohistochemistry; UC, ulcerative colitis.

Article Snippet: Subsequently, the sections were incubated with antibodies of mucin 3 (MUC3; 1:500, PAB031Mu01; Cloud‐Clone Corp.), Claudin‐1 (1:500, ab211737; Abcam Inc.), and tight junction protein 1 (ZO‐1, 1:500, ab276131; Abcam) overnight at 4°C, followed by incubation with goat anti‐rabbit IgG (1: 1,000, ab6721; Abcam) at 37°C for 20 min.

Techniques: Positive Control, Staining, Enzyme-linked Immunosorbent Assay, Expressing, Activity Assay, Immunohistochemistry

Journal: Immunity, Inflammation and Disease

Article Title: Alleviating effect of Nexrutine on mucosal inflammation in mice with ulcerative colitis: Involvement of the RELA suppression

doi: 10.1002/iid3.1147

Figure Lengend Snippet: Restoration of RELA aggravates inflammatory injury in mouse colon tissues. Mice were injected with Ad‐RELA through the mesenteric artery, followed by the 3% DSS and Nexrutine (300 mg/kg) treatments. (A) Body weight change of mice in each group; (B) DAI score of mice in each group; (C) length of whole colon of mice in each group; (D) pathological injury score in mouse colon tissues evaluated by HE staining; (E) concentrations of IL‐1β, IL‐6, TNF‐α, and IL‐10 in mouse colon tissues analyzed by ELISA kits; (F) expression of MUC3, Claudin‐1, and ZO‐1 in mouse colon tissues determined by IHC assay. In each group, n = 8. Differences were analyzed by the unpaired t test (B–D) or two‐way ANOVA (A, E, F). * p < .05 versus the control group; # p < .05 versus the DSS group. DAI, disease activity index; DSS, dextran sulfate sodium; HE, hematoxylin and eosin; IHC, immunohistochemistry.

Article Snippet: Subsequently, the sections were incubated with antibodies of mucin 3 (MUC3; 1:500, PAB031Mu01; Cloud‐Clone Corp.), Claudin‐1 (1:500, ab211737; Abcam Inc.), and tight junction protein 1 (ZO‐1, 1:500, ab276131; Abcam) overnight at 4°C, followed by incubation with goat anti‐rabbit IgG (1: 1,000, ab6721; Abcam) at 37°C for 20 min.

Techniques: Injection, Staining, Enzyme-linked Immunosorbent Assay, Expressing, Activity Assay, Immunohistochemistry

Journal: Inflammatory bowel diseases

Article Title: Aberrant Mucin Expression Profiles Associate With Pediatric Inflammatory Bowel Disease Presentation and Activity.

doi: 10.1093/ibd/izac217

Figure Lengend Snippet: Figure 1. Expression of mucins in the colon of pediatric inflammatory bowel disease (IBD) patients and non-IBD control subjects. A, Relative messenger RNA (mRNA) expression of MUC1, MUC2, MUC3A, MUC3B, MUC4, and MUC13 in inflamed and noninflamed colonic tissue of IBD patients and non-IBD control subjects. Significant differences are indicated by *P < .05; **P < .01; ***P < .001 (1-way analysis of variance or Kruskal-Wallis, Tukey ,and Dunn multiple comparison post hoc test). B, Immunohistochemical analysis of MUC1, MUC2, MUC3, MUC4, and MUC13 expression in colonic biopsies from non-IBD control subjects and IBD patients. Representative images were selected. Scale bars = 20 μm.

Article Snippet: Five-micrometer cross-sections were deparaffinized, rehydrated, and used for immunohistochemical stainings using target specific primary antibodies and visualization with a secondary streptavidin–horseradish peroxidaseconjugated antibody and AEC (3-amino-9-ethylcarbazole) substrate to detect the expression and localization of MUC1 (AF6298; R&D systems; 1:500), MUC2 (NBP1-31,231; Novus Biologicals; 1:2000), MUC3 (NBP2-44,434; Novus Biologicals; 1:100), MUC4 (NBP1-52193; Novus Biologicals; 1:3000), and MUC13 (MABC209; Merck Millipore; 1:1000).

Techniques: Expressing, Control, Comparison, Immunohistochemical staining